Skip to main content

Natera, Inc. (NTRA)

NASDAQ: NTRA · Delayed Price · USD
126.44
+0.08 (0.06%)
Pre-market:Sep 20, 2021 7:04 AM EDT
126.36
5.99 (4.98%)
At close: Sep 17, 4:00 PM
Market Cap11.85B
Revenue (ttm)504.86M
Net Income (ttm)-314.61M
Shares Out93.78M
EPS (ttm)-3.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume560,462
Open120.99
Previous Close120.37
Day's Range119.80 - 126.52
52-Week Range58.70 - 127.19
Beta1.25
AnalystsStrong Buy
Price Target150.11 (+18.8%)
Est. Earnings DateNov 4, 2021

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fert...

IndustryBiotechnology
IPO DateJul 2, 2015
Employees1,815
Stock ExchangeNASDAQ
Ticker SymbolNTRA
Full Company Profile

Financial Performance

In 2020, Natera's revenue was $391.01 million, an increase of 29.33% compared to the previous year's $302.33 million. Losses were -$229.74 million, 84.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Natera stock is "Strong Buy." The 12-month stock price forecast is 150.11, which is an increase of 18.80% from the latest price.

Price Target
$150.11
(18.80% upside)
Analyst Consensus: Strong Buy

News

Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma

AUSTIN, Texas, Sept. 17, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in cell-free DNA testing, today announced new data being presented by the company and its collaborators on the use of...

3 days ago - PRNewsWire

Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to...

AUSTIN, Texas, Sept. 9, 2021 /PRNewswire/ --   Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the launch of Prospera with Q...

1 week ago - PRNewsWire

Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-...

AUSTIN, Texas, Sept. 7, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a leader in transforming care through genetic and cell-free DNA testing, today announced an agreement with NRG Oncology, a Nati...

1 week ago - PRNewsWire

Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test

AUSTIN, Texas, Aug. 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the validation and clinical ava...

2 weeks ago - PRNewsWire

New Strong Sell Stocks for August 10th

THS, ZYME, NTRA, LAWS, and INSW have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2021

Other symbols:INSWLAWSTHSZYME
1 month ago - Zacks Investment Research

Natera to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Aug. 10, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the company's leadership will participate in several...

1 month ago - PRNewsWire

Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook

Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus of $127.49 million. Product rev...

1 month ago - Benzinga

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of -25.71% and 1.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Natera Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 202...

1 month ago - PRNewsWire

Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Sta...

AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, announced that the first patient has been screened in a new phase III trial...

1 month ago - PRNewsWire

Natera Announces Second Quarter 2021 Earnings Conference Call

AUSTIN, Texas, July 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended ...

1 month ago - PRNewsWire

Earnings Preview: Natera (NTRA) Q2 Earnings Expected to Decline

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology val...

1 month ago - PRNewsWire

3 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:ANTMVTNR
1 month ago - Benzinga

New Publication Shows 96% Overall Survival Among Metastatic Colorectal Cancer Patients Who Test MRD-Negative with Sig...

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new peer-reviewed study validating its...

1 month ago - PRNewsWire

Natera Announces Pricing of Follow-On Offering

AUSTIN, Texas, July 21, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,500,0...

1 month ago - PRNewsWire

Natera Launches Proposed Follow-On Offering

AUSTIN, Texas, July 20, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera"), a pioneer and global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offer...

1 month ago - PRNewsWire

Natera Reports Preliminary Second Quarter 2021 Results

AUSTIN, Texas, July 19, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera" or the "Company"), a pioneer and global leader in cell-free DNA testing, today reported preliminary results for the qua...

2 months ago - PRNewsWire

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Color...

AUSTIN, Texas, July 2, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-inf...

2 months ago - PRNewsWire

This Explosive Biotech Is Taking On a Huge New Market

Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

Other symbols:ADPTARKGGH
2 months ago - The Motley Fool

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and  BGI Genomics Co., Ltd. , (300676.SZ), one...

2 months ago - PRNewsWire

Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS

AUSTIN, Texas, June 18, 2021 /PRNewswire/ --  Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS) ha...

3 months ago - PRNewsWire

Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit

AUSTIN, Texas, June 16, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ab...

3 months ago - PRNewsWire

Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracke...

3 months ago - PRNewsWire

Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference

AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific i...

3 months ago - PRNewsWire